Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

NCT02933944 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Changing priorities

Conditions

Rectal Cancer

Interventions

BIOLOGICAL: TG02-treatment
DRUG: Pembrolizumab

Sponsor

Targovax ASA